Personalized Drug Therapy in Diabetics

The definition of personalized medicine for diabetes (PMFD) is the use of information about the genetic makeup of a person with diabetes to tailor strategies for preventing, detecting, treating, or monitoring their diabetes. The practice of PMFD involves four processes. First is the identification of genes and biomarkers for diabetes as well as for obesity, which is the greatest risk factor for type 2 diabetes. Second, after these predictors of diabetes are identified, is allocation of resources to prevent or detect the diabetes and/or obesity phenotype in high-risk individuals, whose risk is based on their genotype. Third is selection of individualized therapies for affected individuals. The selection process involves deciding which drug to prescribe, what dose of drug to use, and which diet to prescribe. The selection process also accounts for which drug is least likely to cause side effects or toxicity. Fourth is measurement of circulating biomarkers of diabetes to monitor the response to prevention or therapy.

 

    Related Conference of Personalized Drug Therapy in Diabetics

    October 21-22 2019

    25th World Congress on Advanced Materials

    Singapore
    February 24-25, 2020

    5th Annual Conference and Expo on Biomaterials

    Berlin, Germany
    March 05-06, 2019

    14th Annual Conference on Stem Cell and Biomaterials

    | Prague ,Czech Republic
    March 16-17, 2020

    World Congress on Carbon and Advanced Energy Materials

    Sydney, Australia
    May 24-25, 2021

    4th Global Meeting on Diabetes and Endocrinology

    Istanbul, Turkey

    Personalized Drug Therapy in Diabetics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in